MEDCL MedinCell S.A.

29.90USD27.26 EUR · EPA-1.37%Mkt Cap: 1.08B USDP/E: —

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. Th…

Institutional holders10 on file

Key Statistics

Company
Market Cap1.08B USD
Enterprise Value1.06B USD
Revenue (TTM)26.63M USD
Gross Profit21.41M USD
Net Income (TTM)-34.32M USD
Revenue/Share0.80 USD
Last Price29.90 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees141
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0004065605
Valuation
P/E (Trailing)—
P/E (Forward)389.43
PEG—
EV/EBITDA-48.21
EV/Revenue39.79
P/S40.39
P/B320.71
EPS (TTM)-1.03 USD
EPS (Forward)0.08 USD
52W Range
21.6060% of range35.51
52W High35.51 USD
52W Low21.60 USD
Profitability
Gross Margin100.00%
Oper. Margin-85.44%
EBITDA Margin-82.54%
Profit Margin-160.27%
ROE-1021.12%
ROA-28.95%
ROIC—
ROCE-23.79%
Growth
Revenue Growth-44.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.93M USD
CapEx (TTM)2.24M USD
FCF Margin-81.49%
FCF Yield-2.02%
Net Debt-14.16M USD
Net Debt/EBITDA0.64
Net Debt/FCF—
Balance Sheet
Debt/Equity18.74
Current Ratio4.67
Quick Ratio4.59
Book Value/Sh0.09 USD
Cash/Share2.59 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)39.68 USD
Upside (mean)+32.7%
Target Range34.00 USD – 44.97 USD
34.00+32.7% to mean44.97
# Analysts9
Ownership
Shares Out.35.97M
Float32.79M
Insiders33.97%
Institutions32.21%
Technical
SMA 5028.14 (+6.2%)
SMA 20027.48 (+8.8%)
Beta0.91
S&P 52W Chg12.00%
Avg Vol (30d)119.54K
Avg Vol (10d)88.68K
Technical Indicators
RSI (14)48.6
MACD0.6085
MACD Signal0.8595
MACD Hist.-0.2511
BB Upper33.45 USD
BB Middle30.52 USD
BB Lower27.59 USD
BB Width19.19%
ATR (14)1.211 USD
Vol Ratio (20d)0.55x

About MedinCell (EPA: MEDCL)

›

MedinCell (EPA: MEDCL) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 141 employees.

The shares were at 27.26 EUR on 19 November 2026, down 3.5% over 52 weeks. Its 52-week range is 19.69 EUR to 32.38 EUR: the price is 15.8% below the high and 38.4% above the low.

Its market capitalisation is 980.51M EUR.

MedinCell reports an operating margin of -85.4% and revenue down 44.6% year over year.

It holds more cash than debt, a net cash position of 12.91M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 9 analysts cover the stock; their mean price target of 36.18 EUR is 32.7% above the current price. The next earnings report is expected on 8 December 2026.